373 related articles for article (PubMed ID: 22861200)
21. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia.
Waldum HL; Rehfeld JF
Scand J Gastroenterol; 2019 Sep; 54(9):1118-1123. PubMed ID: 31524029
[TBL] [Abstract][Full Text] [Related]
22. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
Betton GR; Dormer CS; Wells T; Pert P; Price CA; Buckley P
Toxicol Pathol; 1988; 16(2):288-98. PubMed ID: 2903544
[TBL] [Abstract][Full Text] [Related]
23. Relationship of ECL cells and gastric neoplasia.
Waldum HL; Brenna E; Sandvik AK
Yale J Biol Med; 1998; 71(3-4):325-35. PubMed ID: 10461363
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
Waldum HL; Sørdal Ø; Fossmark R
Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
[TBL] [Abstract][Full Text] [Related]
25. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
26. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus.
Nishi T; Makuuchi H; Weinstein WM
Tokai J Exp Clin Med; 2005 Jul; 30(2):117-21. PubMed ID: 16146202
[TBL] [Abstract][Full Text] [Related]
27. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development.
Kidd M; Modlin IM; Eick GN; Camp RL; Mane SM
Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G191-200. PubMed ID: 16950763
[TBL] [Abstract][Full Text] [Related]
28. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa.
Lamberts R; Brunner G; Solcia E
Digestion; 2001; 64(4):205-13. PubMed ID: 11842276
[TBL] [Abstract][Full Text] [Related]
29. Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis.
Solcia E; Rindi G; Silini E; Villani L
Baillieres Clin Gastroenterol; 1993 Mar; 7(1):149-65. PubMed ID: 7682874
[TBL] [Abstract][Full Text] [Related]
30. [Study on histogenesis of enterochromaffin-like carcinoid in autoimmune atrophic gastritis associated with pernicious anemia].
Macukanović-Golubović L; Katić V; Rancić G; Milenović M; Marjanović G; Golubović Z
Vojnosanit Pregl; 2007 Aug; 64(8):543-8. PubMed ID: 17874722
[TBL] [Abstract][Full Text] [Related]
31. Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: an indirect effect of the histamine H2-receptor antagonist, BL-6341.
Hirth RS; Evans LD; Buroker RA; Oleson FB
Toxicol Pathol; 1988; 16(2):273-87. PubMed ID: 2903543
[TBL] [Abstract][Full Text] [Related]
32. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
Rais R; Trikalinos NA; Liu J; Chatterjee D
Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
[TBL] [Abstract][Full Text] [Related]
33. A gastric neuroendocrine tumor after prolonged use of proton pump inhibitors.
Prado PHT; Paula RV; de Faria ATR; Silva BL; Ardengh JC
Rev Esp Enferm Dig; 2023 Apr; 115(4):209-210. PubMed ID: 36148661
[TBL] [Abstract][Full Text] [Related]
34. Deletion of
Sundaresan S; Kang AJ; Hayes MM; Choi EK; Merchant JL
Gut; 2017 Jun; 66(6):1012-1021. PubMed ID: 26860771
[TBL] [Abstract][Full Text] [Related]
35. Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids.
Azzoni C; Doglioni C; Viale G; Delle Fave G; De Boni M; Caruana P; Ferraro G; Bordi C
Am J Surg Pathol; 1996 Apr; 20(4):433-41. PubMed ID: 8604810
[TBL] [Abstract][Full Text] [Related]
36. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
37. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Fossmark R; Johnsen G; Johanessen E; Waldum HL
Aliment Pharmacol Ther; 2005 Jan; 21(2):149-54. PubMed ID: 15679764
[TBL] [Abstract][Full Text] [Related]
38. Multiple gastric carcinoids and endocrine cell micronests in type A gastritis: Nuclear morphometric and immunohistochemical analysis.
Iwai K; Yao T; Nakamura S; Matsumoto T; Nishiyama K; Iida M; Tsuneyoshi M
Oncol Rep; 2005 Mar; 13(3):397-404. PubMed ID: 15706407
[TBL] [Abstract][Full Text] [Related]
39. Serum gastrin and gastric enterochromaffin-like cells during estrous cycle, pregnancy and lactation, and in response to estrogen-like agents in rats.
Vigen RA; Chen D; Syversen U; Stunes K; Hakanson R; Zhao CM
J Physiol Pharmacol; 2011 Jun; 62(3):335-40. PubMed ID: 21893694
[TBL] [Abstract][Full Text] [Related]
40. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
Eslami L; Nasseri-Moghaddam S
Arch Iran Med; 2013 Aug; 16(8):449-58. PubMed ID: 23906249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
